RANKL Blockade Reduces Cachexia and Bone Loss Induced by Non‐Metastatic Ovarian Cancer in Mice

ABSTRACT Tumor‐ and bone‐derived soluble factors have been proposed to participate in the alterations of skeletal muscle size and function in cachexia. We previously showed that mice bearing ovarian cancer (OvCa) exhibit cachexia associated with marked bone loss, whereas bone‐targeting agents, such...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of bone and mineral research Vol. 37; no. 3; pp. 381 - 396
Main Authors:	Pin, Fabrizio, Jones, Alexander J, Huot, Joshua R, Narasimhan, Ashok, Zimmers, Teresa A, Bonewald, Lynda F, Bonetto, Andrea
Format:	Journal Article
Language:	English
Published:	Hoboken, USA John Wiley & Sons, Inc 01.03.2022 Oxford University Press
Subjects:	Animals Antineoplastic drugs ANTIRESORPTIVE TREATMENTS Antitumor agents Atrophy Bisphosphonates Body composition BONE Bone Diseases, Metabolic - pathology Bone loss Bone mass Bone resorption Bone tumors Bone turnover CACHEXIA Cachexia - complications Cachexia - drug therapy CANCER Collagen Drug development Female Humans Ligands Metastases Metastasis Mice MUSCLE Muscle, Skeletal - pathology Muscular Atrophy - pathology Musculoskeletal system Myotubes Ovarian cancer Ovarian Neoplasms - complications Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology RANKL Skeletal muscle Therapeutic targets TRANCE protein MUSCLE CACHEXIA RANKL BONE ANTIRESORPTIVE TREATMENTS CANCER
ISSN:	0884-0431, 1523-4681, 1523-4681
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!